Physician profile
Surena Namdari
NPI 1255539938
$1,783,358.47
in general payments reported to CMS, 2019-2025
21 companies · $657K in 2025
The $657K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149K · 2020: $152K · 2021: $134K · 2022: $179K · 2023: $282K · 2024: $232K · 2025: $657K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $707K · Consulting Fee: $438K · Travel and Lodging: $23K · Food and Beverage: $1,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $707,362.77 |
| Consulting Fee | $437,614.00 |
| Travel and Lodging | $23,084.72 |
| Food and Beverage | $1,974.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, Lp | $1,691,906.93 | 2019-2025 | Djo Surgical |
| Insight Medical Systems, INC. | $40,238.40 | 2023-2024 | Arvis |
| Biedermann Motech, INC. | $22,373.95 | 2019-2023 | Distal Radius Plating System 2.0, Proximal Humerus Plating System, Olecranon Plating System |
| Medical Device Business Services, INC. | $7,221.92 | 2019-2024 | |
| Davol INC. | $7,165.52 | 2021-2025 | |
| Synthes USA Products LLC | $4,463.55 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $4,140.00 | 2022 | |
| Liberty Surgical INC. | $2,828.71 | 2019-2020 | |
| Acelrx Pharmaceuticals, INC. | $2,000.00 | 2021 | |
| Stryker Corporation | $277.63 | 2021-2023 | Salvation |
| Catalyst Orthoscience | $275.40 | 2019-2022 | |
| Arthrex, INC. | $259.61 | 2023-2025 | Arthrex |
| Restor3d, INC. | $104.69 | 2022 | |
| Ermi LLC | $24.52 | 2019 | |
| Depuy Synthes Sales INC. | $24.46 | 2019-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.81 | 2025 | Intellis Adaptivestim |
| Vertex Pharmaceuticals Incorporated | $18.05 | 2025 | |
| Horizon Therapeutics Plc | $12.32 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surena Namdari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.